- Open Access
Sterile alpha motif and histidine/aspartic acid domain-containing protein 1 (SAMHD1)-facilitated HIV restriction in astrocytes is regulated by miRNA-181a
© Pilakka-Kanthikeel et al.; licensee BioMed Central. 2015
- Received: 15 October 2014
- Accepted: 18 March 2015
- Published: 8 April 2015
Although highly active antiretroviral therapy (HAART) has significantly reduced the morbidity and mortality in HIV patients, virus continues to reside in the central nervous system (CNS) reservoir. Hence, a complete eradication of virus remains a challenge. HIV productively infects microglia/macrophages, but astrocytes are generally restricted to HIV infection. The relative importance of the possible replication blocks in astrocytes, however, is yet to be delineated. A recently identified restriction factor, sterile alpha motif and histidine/aspartic acid domain-containing protein 1 (SAMHD1), restricts HIV infection in resting CD4+T cells and in monocyte-derived dendritic cells. However, SAMHD1 expression and HIV-1 restriction activity regulation in the CNS cells are unknown. Though, certain miRNAs have been implicated in HIV restriction in resting CD4+T cells, their role in the CNS HIV restriction and their mode of action are not established. We hypothesized that varying SAMHD1 expression would lead to restricted HIV infection and host miRNAs would regulate SAMHD1 expression in astrocytes.
We found increased SAMHD1 expression and decreased miRNA expression (miR-181a and miR-155) in the astrocytes compared to microglia. We report for the first time that miR-155 and miR-181a regulated the SAMHD1 expression. Overexpression of these cellular miRNAs increased viral replication in the astrocytes, through SAMHD1 modulation. Reactivation of HIV replication was accompanied by decrease in SAMHD1 expression.
Here, we provide a proof of concept that increased SAMHD1 in human astrocytes is in part responsible for the HIV restriction, silencing of which relieves this restriction. At this time, this concept is of theoretical nature. Further experiments are needed to confirm if HIV replication can be reactivated in the CNS reservoir.
HIV-1 infection of astrocytes results in an initial productive, non-cytopathogenic infection that diminishes to a poorly productive, persistent infection [1,2]. Even though astrocyte infection is ‘restricted,’ their infection results in cellular dysfunction, contributing to the development of HIV-associated neurocognitive disorders (HAND) . Though astrocytes lack surface CD4 receptor, astrocytes get infected by a CD4-independent viral entry, through the mannose receptor that is expressed on the surface of astrocytes [4-6]. Infected astrocytes initiate productive infection of HIV-permissive blood-derived cells in co-culture experiments [7,8]. Although potent highly active antiretroviral therapy (HAART) suppresses plasma viremia to undetectable levels , it is unable to eliminate the virus from quiescent reservoirs [10-12] and/or from sanctuaries like the brain [13-15]. The astrocytic reservoir protected from HAART is capable of initiating new infections upon treatment discontinuation and constitutes an important hindrance to HIV clearance from the central nervous system (CNS) [7,16,17].
Deciphering the innate molecular mechanisms that restrict HIV replication and establish persistent reservoirs is essential for developing strategies to reactivate the reservoir. Overcoming the blocks in HIV replication can lead to the upregulation of the gene expression, making these cells available to immune surveillance and HAART targeting. Efficient replication is blocked in astrocytes at different steps of the HIV life cycle [1,8,18]. Although several pre-transcriptional and post-transcriptional mechanisms are shown to contribute to HIV latency, whether SAMHD1 contributes to the viral restriction in astrocytes is not known [19,20].
Specific ‘intrinsic host restriction’ factors restrict virus replication in mammalian cells. Some cells constitutively express these factors, and in others, they are induced by interferons as part of the innate immune response. Apolipoprotein B mRNA-editing enzyme 3G (APOBEC-3G) , bone marrow stromal cell antigen 2 (BST-2) , tripartite motif protein 5 alpha (TRIM-5α) , and cellular miRNAs  are examples of restriction factors targeting HIV-1. SAMHD1, a recently identified nuclear protein restriction factor, hydrolyzes cellular deoxynucleotide (dNTP) pools and hampers retrovirus reverse transcription . Due to the limited deoxynucleotide substrate availability, SAMHD1 inhibits HIV infection of myeloid cells and naïve CD4+T cells [26,27]. However, SAMHD1-mediated restriction has not been explored in CNS cells. We hypothesized that increased expression of SAMHD1 restricts HIV infection in astrocytes. In this study, we compared the expression of SAMHD1 in astrocytes and microglia and correlated with the HIV replication.
Some studies have shown that SAMHD1 phosphorylation status correlates with the restriction activity but not its dNTPase activity . However, little is known about the post-transcriptional regulation of SAMHD1 expression. MicroRNAs have been implicated in the HIV gene expression and latency in CD4+T cells [29-31]. It is not known whether miRNA modulation plays a role in HIV-1 restriction in astrocytes, and whether miRNA regulates SAMHD1 gene expression. Hence, in this report, we also examined SAMHD1 regulation by miRNA. Here, we report that astrocytes display higher SAMHD1 expression compared to microglia, which is in part accountable for HIV restriction in the astrocytes and miR-181a regulates SAMHD1.
HIV infection in astrocytes is restricted
Astrocytes display higher SAMHD1 expression
Though SAMHD1 has been shown to be responsible for the non-susceptibility of myeloid cells, resting CD4 T cells and macrophages to HIV infection [26,27], its expression has not been evaluated in CNS cells yet. Here, we compared the expression of SAMHD1 in two primary CNS cell types (astrocytes and microglia), which are differentially infected by HIV. We performed real-time PCR analysis to quantify SAMHD1 mRNA expression. By comparing SAMHD1 expression in these two cell types, we expected to see a differential expression of SAMHD1 in non-productively (astrocytes) and productively (microglia) infected cells. As expected, we found that constitutive expression of SAMHD1 mRNA was sevenfold higher in astrocytes compared to microglia (Figure 1C). To further confirm, if the gene expression observed corresponds to protein expression, we performed immunoblotting to detect SAMHD1 protein levels. Similar to gene expression pattern, astrocytes displayed increased SAMHD1 protein expression (Figure 1D). This was further confirmed by intra cellular expression by flow cytometry (Figure 1E).
HIV replication kinetics correlates with SAMHD1 expression
SAMHD1 hydrolyzes dNTPs and lowers their concentrations to a level that is suboptimal for reverse transcription of viral RNA . We asked whether the SAMHD1 expression plays a role in the restriction of HIV replication in astrocytes and examined whether SAMHD1 expression is modulated by HIV infection. Reverse transcriptase activity measurement was done in culture supernatant at 3, 5, 7, 10, 15, and 20 dpi. The reverse transcriptase assay estimates the quantitative determination of reverse transcriptase (RT) activity. Consistent with p24 level, we found higher reverse transcriptase activity in astrocytes at day 5 post infection, which decreased thereafter (Figure 1F). Reverse transcriptase activity was significantly higher in microglia compared to astrocytes at all-time points (Figure 1F). This suggests that low reverse transcriptase activity contributes towards the restriction of HIV infection observed in astrocytes. Subsequently, we analyzed SAMHD1 mRNA expression in the cells at these same time points following infection and compared with baseline. SAMHD1 mRNA expression in astrocytes was higher at 3 dpi compared to baseline. At day 5, SAMHD1 expression was decreased, which further increased on day 7 and remained high thereafter (Figure 1G). Interestingly, in astrocytes, SAMHD1 gene expression was lowest at day 5, when the p24 level was the highest. SAMHD1 protein expression was also lower on day 5 (Figure 1H). Even though microglia did not show much significant change in the SAMHD1 mRNA expression during the course of infection, the increase in SAMHD1 protein expression was more prominent than gene expression during HIV infection (Figure 1H).
SAMHD1 silencing relieves the ‘restriction’
In order see if the SAMHD1-mediated repression of HIV-1 replication is due to its ability to repress reverse transcription, we evaluated whether the process of reverse transcription occurred efficiently following SAMHD1 silencing. Infected astrocytes were analyzed by qPCR for early reverse transcription products at 72 h post infection using a set of primers specific for long terminal repeat (LTR) R/U5 (short first transcript). Sequences of PCR primers have been previously described . We saw that SAMHD1 inhibition increased LTR R/U5 approximately 2.5-fold (Figure 2C). Negative control siRNA transfection did not show any difference in the LTR R/U5 expression. These results indicate that SAMHD1 has an effect at the reverse transcription phase in astrocytes. Interestingly, SAMHD1 silencing did not show any significant change in the p24 in microglia (not shown).
We treated the astrocytes with a reverse-transcriptase inhibitor, azidothymidine triphosphate (AZTTP, 100 nm) 6 h before siRNA transfection. Treatment with AZTTP significantly inhibited the p24 production in infected astrocytes (390 ± 37.86 to 30.67 ± 3.48, 93% decrease; Figure 2B). SAMHD1 siRNA-mediated increase in the p24 level was also inhibited by AZTTP (1,383 ± 169.1 to 250.3 ± 28.87 pg/ml, 82% decrease). Similar to the observation in p24 level, AZTTP treatment suppressed SAMHD1 siRNA-mediated increase in LTR R/U5 expression (Figure 2C). Further, we infected the astrocytes with VSV-G pseudotype virus following SAMHD1 siRNA transfection. We found approximately two fold increase in luciferase activity after SAMHD1 siRNA transfection (Figure 2D). This further confirms that SAMHD1 has a role in suppression of HIV-1 replication in astrocytes, even though the virus gets rid of the entry restriction. This is in accordance with the previous reports in resting CD4 T cells and myeloid cells explaining that SAMHD1 is responsible for the efficient reverse transcription [27,34,35]. These results confirm the role of SAMHD1 as a restriction factor that facilitates in HIV-1 restriction in astrocytes and silencing SAMHD1 relieves the ‘restriction.’ Additional investigations are needed to confirm that the restriction is at the level of reverse transcription. However, the possibility of additional SAMHD1-dependent/independent mechanisms cannot be excluded.
Reactivation decreases SAMHD1 expression
Neutralizing the miRNAs or histone deacetylase (HDAC) inhibitors treatment in latently infected cells has shown to revert the latency and reactivate the HIV infection [36-38]. We wanted to see if the reactivation of virus is accompanied by change in SAMHD1 expression. An in vitro model mimicking latent infection in astrocyte was prepared as described by Gray et al. to make sure the cells were in latent stage before trichostatin A (TSA) treatment . Astrocytes were infected with the pseudotyped virus in the presence or absence of the integrase inhibitor raltegravir for 2 days. Cells were then treated with TSA and reactivation from latency was assessed by measuring luciferase activity. As shown in Figure 2E, TSA treatment induced reactivation from raltegravir-treated cells. This was in agreement with the abovementioned reports, which showed an increase in HIV replication with TSA treatment. We further evaluated the SAMHD1 expression in TSA treated cells. We found that TSA treatment was accompanied by a decrease in the SAMHD1 expression both in gene and protein level (Figure 2F, G).
miR-181a and −155 targets SAMHD1 in astrocytes
Neutralizing the miRNAs in latently infected cells has shown to revert the latency . Yet, the information available about role of miRNAs in CNS HIV replication is limited. Moreover, mechanism of SAMHD1 regulation is also not known. Since both miRNAs and SAMHD1 plays a role in HIV replication, we asked whether SAMHD1-mediated HIV-1 restriction in astrocytes is regulated by miRNA-mediated translational inhibition. We screened web-based tools TargetScan (http://www.targetscan.org/) and http://www.mirdb.org to identify potential miRNAs that can target SAMHD1 (by searching for the presence of conserved 8mer and 7mer sites that match the seed region of each miRNA). We were able to identity few miRNAs (miR-124, −150, −155, −181a-d, −490, and −496) that have binding sites on SAMHD1. We concentrated our further experiments on miR-155 and -181a, because of their importance in the brain and latency [40-43].
miR-181a/miR-155 inhibition increases HIV replication
Further, we wished to determine whether miRNA(s) have a direct role in the regulation of HIV-1 gene expression or whether the miRNA-mediated regulation of HIV-1 replication is through its ability to modulate SAMHD1. We co-transfected SAMHD1 siRNA and miR-181a inhibitor in astrocytes, followed by HIV infection. As shown in previous experiment, SAMHD1 silencing increased the p24 level, whereas miR-181a inhibition decreased p24 level (Figure 4C). Interestingly, co-transfection did not have significant change in p24 level compared to the untreated control. This data confirms that miR-181a/miR-155-mediated HIV regulation is by inhibiting SAMHD1.
Astrocytes, which constitute 40% to 70% of total cells in the CNS , perform key regulatory functions critical to brain function. The different CNS cell types are differentially infected with HIV; microglia being highly susceptible, astrocytes moderately restrictive, and neurons highly restrictive. Despite the lack of CD4 receptors, astrocytes become infected via CD4-independent mechanism [6,44]. In line with the earlier studies [1,2], we also found low level of HIV replication in astrocytes compared to microglia. After the initial productive phase, infection subsides to a persistent stage in astrocytes, which goes in hand with reports from other investigators [1,2,32]. Infected astrocytes produce very low levels of virus even in the acute phase in contrast to infection of T-lymphocytes [45,46]. Our results with pseudotyped virus confirm that regardless of the entry routes, there are post-entry blocks to infection in astrocytes. Though the introduction of potent HAART has significantly controlled the viral replication in HIV patients, the current antiviral strategies target only actively replicating virus. Having said that, persistently infected brain astrocytes would not be susceptible to antiviral drugs, allowing the virus to persist in these reservoirs. Hence, the complete eradication of the virus from the host remains an impossible task. Several post-transcriptional and post-translational mechanisms [19,20], a number of host restriction factors [21,22], and certain cellular miRNAs  have been reported to hinder retroviral replication in astrocytes contributing to HIV latency.
SAMHD1, a recently identified nuclear protein restriction factor, is highly expressed in HIV-1 non-permissive cells, whereas it is absent from HIV-1-sensitive T-cell lines such as Jurkat, SupT1, human peripheral blood acute lymphoid leukemia, and U937 . Since SAMHD1 has not been studied in CNS cells, our aim in this study was to explore the role of SAMHD1 in CNS cells. And we found that astrocytes and microglia express differential endogenous levels of SAMHD1, suggesting that possibly the higher level of SAMHD1 contribute towards HIV restriction in astrocytes. Ours is the first study presenting the role of SAMHD1 in astrocytes.
We found higher reverse transcriptase activity in microglia compared to astrocytes, suggesting low reverse transcriptase activity may be responsible for the restriction of HIV infection observed in astrocytes. Our results also substantiate that decrease in viral replication in astrocytes was in correlation with the increased expression of SAMHD1 and depletion of cellular SAMHD1 in astrocytes is sufficient to alleviate the restriction to HIV infection. This suggests that replication kinetics of the virus follows an inverse relation with SAMHD1 and confirms that SAMHD1 is significantly regulated over the course of infection in astrocytes. Interestingly, SAMHD1 silencing did not show any significant change in the infection in microglia. Our results support the role of SAMHD1 as a restriction factor that facilitates in HIV-1 restriction in astrocytes. Since the role of SAMHD1 is to deplete dNTPs required for RT, we feel that SAMHD1-mediated repression of HIV-1 replication in astrocyte is also due to its ability to repress RT. This goes in hand with the previous reports of SAMHD1 responsible for suboptimal reverse transcription of viral RNA in T cells and DCs . However, SAMHD1 may not be the only restriction factor playing a role in astrocytes. The possibility of additional SAMHD1-dependent/independent mechanisms cannot be excluded.
Complete eradication of HIV is possible only if HAART regimens totally stop all new infections of susceptible cells, along with flushing out existing reservoirs and blocking formation of additional long-lived viral reservoirs or reactivating reservoirs in chronically infected patients on HAART [47,48]. To reactivate viral replication, it is necessary to understand the regulatory mechanisms involved in establishing persistent reservoirs. We found that reactivation of viral replication by HDAC inhibitor, TSA, is accompanied by decrease in SAMHD1 expression. This was in contrast to a recent report showing increase in SAMHD1 expression in CD4-T cells with TSA exposure . De Silva et al. indicated in their study that HDAC inhibition did not significantly change the SAMHD1 protein expression . Though we are not sure the reason for this difference, this suggests that SAMHD1 may be subjected to post-transcriptional regulation. Even though, the restricted HIV-1 replication in myeloid cells, resting T-cells and macrophages has been linked to SAMHD1 expression, little is known about its regulatory mechanism. So, in our next set of experiments, we focused our attention on the molecular mechanism of SAMHD1 regulation.
The miRNAs induce mRNA cleavage or translation repression by targeting complementary or partly complementary sequence in the 3′-untranscribed region (UTR) of target mRNAs . Certain cellular miRNAs have a physiological role in controlling HIV-1 replication and in the maintenance of HIV-1 latency in the peripheral cells [29-31]. We found six miRNAs (miR-124, −150, −155, −181a-d, −490, and −496) to have binding site on SAMHD1, suggesting that SAMHD1 may be regulated by these miRNAs. miR-181 is reported to be very strongly expressed in the brain [41-43], downregulation of which contributes to accelerated HIV-associated dementia , and miR-155 is reportedly absent from latently infected cells . Hence, we concentrated our further experiments on these two miRNAs. In our efforts to verify the role of these miRNAs in the regulation of SAMHD1 and HIV, we saw that modulation of these miRNAs had an impact on the expression of SAMHD1 and also on HIV-1 replication. Combination of these two miRNA inhibitors resulted in a substantial increase in SAMHD1 expression. Interestingly, miR146a (non-targeting miRNA) inhibition resulted in a slight increase, which was unexpected. This may be because, miR146a controls HIV replication through some other means (other than SAMHD1). The restriction in the astrocytes was alleviated miRNA overexpression, which was mediated by the change in SAMHD1 expression. Viral miR-K12-11, an orthologue of cellular miR-155, has been reported to target SAMHD1 , which goes in hand with our finding. To the best of our knowledge, ours is the first study showing miR181a regulation of SAMHD1 in astrocytes.
In summary, the importance of our study is that it provides a proof of concept that SAMHD1 facilitates HIV-1 restriction in astrocytes and miR-181a/miR-155 regulates SAMHD1 expression. Overexpression of these cellular miRNAs or suppression of SAMHD1 removed the inhibition of HIV-1 replication resulting in increased viral production from the astrocytes. As a result, this may allow persistently infected astrocytes to be exposed to immune surveillance or for the action of HAART. At this time, this concept is of theoretical nature, as we did not have any in vivo data. Future in vivo experiments are needed to evaluate if optimal combinations of miRNA or SAMHD1 siRNA delivered to astrocytes along with HAART could reactivate the HIV replication in persistently latent cells.
Cells and reagents
The primary astrocytes (HA #1800) and microglia (HM #1900) types are isolated from normal human brain and are commercially available (Sciencell Research Laboratories, Carlsbad, CA, USA). Cells were grown in the specified media as recommended by the manufacturer. Depending upon the experiments, cells were cultured at a concentration of 5 × 105 cells/ml in six-well plates (for transfection experiment) or 1 × 106 cells/ml and allow them to reach at least 70% confluency before any further treatment.
Microglia and astrocytes (1 × 106 cells/ml) were infected with HIV-1Bal, (NIH AIDS Research and Reference Reagent Program; catalog no. 510) at a concentration of HIV-1 p24 100 ng/106 cells for 24 h. Cells were washed to remove unbound virus and replenished with fresh media.
SAMHD1 mRNA quantification
For SAMHD1 mRNA quantification, total cellular RNA was extracted using the RNeasy mini kit (Qiagen, Limburg, the Netherlands) according to the manufacturer’s guidelines. One hundred nanograms of the total RNA from each cell type was used as a template for first-strand cDNA synthesis using high-capacity reverse transcriptase kit (Applied Biosystems, Waltham, MA, USA, #4368814). SAMHD1 mRNA was quantitated by SYBER Green-based quantitative real-time PCR (Stratagene-3000; Stratagene, La Jolla, CA, USA) analysis was performed using the specific primers. Quantification of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA was carried out for normalization. Relative expression of mRNA species was calculated using the comparative C T method.
Immunoblotting of SAMHD1
To assess SAMHD1 protein levels, cells were harvested after respective treatments and/or transfection (supernatant was collected for the detection of p24 and reverse transcriptase activity assay). Cells were washed twice with PBS and homogenized in cell lysis buffer (MPER mammalian protein extraction reagent, Thermo Scientific, Waltham, MA, USA) supplemented with protease inhibitor mixture (Thermo Scientific, Waltham, MA, USA) by incubating on ice for 15 min. The homogenates were centrifuged at 10,000 rpm for 10 min and the supernatant was used for further analysis. Protein quantification was carried out by using Bio-Rad protein assay kit (Bio-Rad Laboratories Inc., Hercules, CA, USA). Thirty micrograms of whole cell lysate was electrophoretically separated on an SDS-polyacrylamide gel. Separated proteins were transferred to nitrocellulose paper for 90 min at 100 V, using a wet electroblotting system (Bio-Rad Laboratories Inc., Hercules, CA, USA). Blots were blocked for 1 h in 5% non-fat dry milk in Tris-buffered saline-Tween (TBST) (20 mM Tris, 150 mM NaCl, 0.1% Tween 20, pH 7.5), followed by incubation overnight with the primary antibody (1:500 SAMHD1 polyclonal antibody; # sc-86212, Santa Cruz Biotechnology, Inc., Dallas, Texas, USA) in 1% milk solution. After several washes in TBST, the membranes were incubated in TBST/2% non-fat dry milk, containing the donkey anti-goat coupled to horse radish peroxidase (1:50,000 dilution; #sc-2020, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) for 1 h at RT. After washes in TBST, immunoreactivity was visualized using Western blotting detection reagent (SuperSignal West Pico enhancer, Thermo Scientific, Waltham, MA, USA). Expression of GAPDH (monoclonal mouse, Sigma-Aldrich, St. Louis, MO, USA, 1:50,000) was used as loading control.
SAMHD1 siRNA transfection
SAMHD1-siRNA and scrambled siRNA were procured from Santa Cruz Biotechnology. Astrocytes (2 x 105) were seeded into antibiotic-free Dulbecco's Modified Eagle’s medium (DMEM) supplemented with 10% FBS 24 h before transfection. On day of transfection, 75 pmols siRNA duplex and 6 μl of siRNA transfection reagent (sc-29528) are diluted into 100 μl serum and antibiotic-free siRNA transfection medium (sc-36868) in separate tubes. Both the solutions are mixed gently and incubated for 30 min at room temperature. This mixture is diluted with 0.8 ml siRNA transfection medium, overlayed onto the cells and incubated at 37°C in a CO2 incubator. After 5 h, cells are supplemented with 1 ml of normal growth medium containing two times the normal serum and antibiotics concentration without removing the transfection mixture. Cells were left untreated on infected with HIV and incubated for another 72 h. A second round of transfection was performed 24 h after the first transfection, whenever it was needed. Cells were harvested for RNA or protein isolation, and supernatant collected for p24 and RTase measurements.
miRNA expression assay
Total RNA was isolated using the mir-Vana miRNA isolation (#:1560; Ambion), in accordance with the manufacturer’s protocol. RNA concentrations were determined and 2 ng of each RNA sample were used for cDNA synthesis using TaqMan MicroRNA reverse transcription kit. Quantitative real-time RT-PCR (qRT-PCR) was performed using specific primers for miR-155 and miR-181a (Applied Biosystems, Waltham, MA, USA). All reactions were analyzed using StepOne Real-Time PCR System (Applied Biosystems, Waltham, MA, USA). miRNA levels were normalized to U6 snRNA control and the cycle threshold (Ct) values were calculated.
Cells in 12-well plates were transfected either with anti-miR inhibitor or miRNA mimic (Applied Biosystems, Waltham, MA, USA) in inhibition or in overexpression experiments respectively, using Lipofectamine according to the manufacturer’s instructions. Briefly, 5 ul Lipofectamine was added to 200 ml of serum free medium (DMEM + F10) per condition for 5 min followed by incubation with anti-miR or miR-mimic at a final concentration of 50 nM. The volume was adjusted to 1 ml with medium containing 10% FCS and added to the cells. Following transfection, cells were treated with HIV or left uninfected for 72 h after which the cells were harvested for RNA or protein isolation, and supernatant collected for p24 and RTase measurements.
Following HIV infection/transfection, cells were collected, RNA isolated (RNAeasy mini kit; Qiagen, Limburg, the Netherlands) and qRT-PCR run to amplify a 180 bp fragment in the LTR-R/U5 region that represents early stages of reverse transcription of HIV-1 using the following primers: 5′-primer, 5′-TCTCTCTGGTTAGACCAGATCTG; 3′-primer, and 5′-ACTGCTAGAGATTTTCCACACTG.
Reverse transcriptase activity
Reverse transcriptase activity of samples was assayed using a colorimetric reverse transcriptase assay (Roche Applied Science, Basel, Switzerland). Supernatants were collected at the end of infection, and the viruses were pelleted by ultra-centrifugation at 100,000 g for 120 min at 4°C. Virus pellets were resuspended and lysed by adding 40 μl lysis buffer, followed by addition of 20 μl of mixture containing template/primer hybrid and nucleotide, and incubated for 15 h at 37°C. Samples were then processed as per kit protocol for ELISA and absorbance read at 405 nm. Reactions were performed in triplicate, and experiments were performed thrice and the results averaged.
p24 Ag concentration in the culture supernatants were assayed in an ELISA method using ZeptoMetrix RETRO-TEK ELISA kit (ZeptoMetrix Corporation, Buffalo, NY, USA) as per manufacturer’s recommendations.
For the TSA (Cell Signaling, Danvers, MA, USA) treatment, after reaching confluency, the cells were with 50 nM TSA for 24 h and washed and proceeded with cell isolation for RT-PCR and Western blot.
Cells (1 × 106) were permeabilized with perm wash buffer and stained with fluorescein isothiocyanate (FITC)-conjugated SAMHD1 monoclonal ab (Abcam plc, Cambridge, MA, USA; #ab128107) at 4°C for 20 min, and washed. Samples were acquired using FACSCalibur (BD Biosciences, San Jose, CA, USA) with collection of 100,000 cells and analyzed using FlowJo software. SAMHD1 ab was conjugated to FITC by EasyLink FITC Conjugation Kit (Abcam plc, Cambridge, MA, USA; #ab102885) as per the kit protocol.
Plasmids, transfections, and luciferase assay
The following plasmids were obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: pHIV-CAT (cat#2619) from Dr. Gary Nabel and Dr. Neil Perkins; pSVTat (cat#294) from Dr. Alan Frankel; pNL4-3-Luc.R−E−(cat#3418) Dr. Nathaniel Landau, Aaron Diamond AIDS Research Center, The Rockefeller University; and pHEF-VSV-G from Dr. Lung-Ji Chang. Amphoteric HIV pseudoviruses containing the firefly luciferase gene were produced by transfecting 293 T cells with pHEF-VSV-G (10 μg) and pNL4-3. Luc.R-E- (10 μg) in 90-mm culture dishes. Briefly, plasmid DNA was diluted in Opti-MEM serum free media (Invitrogen, Carlsbad, CA, USA). Lipofectamine LTX and PLUS reagent (Invitrogen, Carlsbad, CA, USA) diluted in equal volume and added to diluted DNA at a 1:1 ratio. Mixture was incubated for 5 min to allow formation of DNA-liposome complexes. Culture supernatants containing the pseudoviruses were collected 72 h post-transfection and clarified by centrifugation at 400 g. Pseudoviruses were competent for single round of replication. Astrocytes infected with the HIV-luciferase pseudovirus (20 ng) were harvested 3 dpi, washed with PBS and lysed. Lysates were pre-cleared by centrifugation at 12,000 g for 2 min at 4°C. Luciferase concentration in whole cell lysates from cells was determined using a Luciferase assay system (Promega, Madison, WI, USA), according to the manufacturer’s instructions (Technical Bulletin #TB281). One hundred microliters of luciferase assay reagent were dispensed in a 96-well microplate (Costar, Corning, NY), 20 μl of cell lysate added to each well, mixed by pipetting, and read on a luminometer (Synergy HT, BioHIT, Sartorius AG, Goettingen, Germany).
Results are presented as mean ± SE of three independent experiments. Differences between treated and untreated cultures were compared by Student’s t-test. Comparisons of more than two groups were made using analysis of variance (ANOVA) (Kruskal-Wallis). Data were analyzed using Graphpad Prism version 5.0 software and statistical significance considered when P value ≤0.05.
This work was supported partly by grants from National Institute of Health (R37DA025576, R01MH085259) and Pilot grant (800004604) from the Florida International University Foundation
- Gorry P, Purcell D, Howard J, McPhee D. Restricted HIV-1 infection of human astrocytes: potential role of nef in the regulation of virus replication. J Neurovirol. 1998;4:377–86.View ArticlePubMedGoogle Scholar
- Messam CA, Major EO. Stages of restricted HIV-1 infection in astrocyte cultures derived from human fetal brain tissue. J Neurovirol. 2000;6 Suppl 1:S90–4.PubMedGoogle Scholar
- Heaton RK, Clifford DB, Franklin Jr DR, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010;75:2087–96.View ArticlePubMed CentralPubMedGoogle Scholar
- Gray LR, Roche M, Flynn JK, Wesselingh SL, Gorry PR, Churchill MJ. Is the central nervous system a reservoir of HIV-1? Curr Opin HIV AIDS. 2014;9:552–8.View ArticlePubMedGoogle Scholar
- Liu Y, Liu H, Kim BO, et al. CD4-independent infection of astrocytes by human immunodeficiency virus type 1: requirement for the human mannose receptor. J Virol. 2004;78:4120–33.View ArticlePubMed CentralPubMedGoogle Scholar
- Sabri F, Tresoldi E, Di Stefano M, et al. Nonproductive human immunodeficiency virus type 1 infection of human fetal astrocytes: independence from CD4 and major chemokine receptors. Virology. 1999;264:370–84.View ArticlePubMedGoogle Scholar
- Dewhurst S, Bresser J, Stevenson M, Sakai K, Evinger-Hodges MJ, Volsky DJ. Susceptibility of human glial cells to infection with human immunodeficiency virus (HIV). FEBS Lett. 1987;213:138–43.View ArticlePubMedGoogle Scholar
- Tornatore C, Nath A, Amemiya K, Major EO. Persistent human immunodeficiency virus type 1 infection in human fetal glial cells reactivated by T-cell factor(s) or by the cytokines tumor necrosis factor alpha and interleukin-1 beta. J Virol. 1991;65:6094–100.PubMed CentralPubMedGoogle Scholar
- Geeraert L, Kraus G, Pomerantz RJ. Hide-and-seek: the challenge of viral persistence in HIV-1 infection. Annu Rev Med. 2008;59:487–501.View ArticlePubMedGoogle Scholar
- Bailey JR, Sedaghat AR, Kieffer T, et al. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J Virol. 2006;80:6441–57.View ArticlePubMed CentralPubMedGoogle Scholar
- Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A. 1997;94:13193–7.View ArticlePubMed CentralPubMedGoogle Scholar
- Nickle DC, Jensen MA, Shriner D, et al. Evolutionary indicators of human immunodeficiency virus type 1 reservoirs and compartments. J Virol. 2003;77:5540–6.View ArticlePubMed CentralPubMedGoogle Scholar
- McGee B, Smith N, Aweeka F. HIV pharmacology: barriers to the eradication of HIV from the CNS. HIV Clin Trials. 2006;7:142–53.View ArticlePubMedGoogle Scholar
- Sawchuk RJ, Yang Z. Investigation of distribution, transport and uptake of anti-HIV drugs to the central nervous system. Adv Drug Deliv Rev. 1999;39:5–31.View ArticlePubMedGoogle Scholar
- Solas C, Lafeuillade A, Halfon P, Chadapaud S, Hittinger G, Lacarelle B. Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2003;47:238–43.View ArticlePubMed CentralPubMedGoogle Scholar
- Chiodi F, Fuerstenberg S, Gidlund M, Asjo B, Fenyo EM. Infection of brain-derived cells with the human immunodeficiency virus. J Virol. 1987;61:1244–7.PubMed CentralPubMedGoogle Scholar
- Ellis RJ, Rosario D, Clifford DB, et al. Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study. Arch Neurol. 2010;67:552–8.View ArticlePubMed CentralPubMedGoogle Scholar
- Neumann M, Felber BK, Kleinschmidt A, et al. Restriction of human immunodeficiency virus type 1 production in a human astrocytoma cell line is associated with a cellular block in Rev function. J Virol. 1995;69:2159–67.PubMed CentralPubMedGoogle Scholar
- Colin L, Van Lint C. Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology. 2009;6:111.View ArticlePubMed CentralPubMedGoogle Scholar
- Schiralli Lester GM, Henderson AJ. Mechanisms of HIV transcriptional regulation and their contribution to latency. Mol Biol Int. 2012;2012:614120.View ArticlePubMed CentralPubMedGoogle Scholar
- Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature. 2002;418:646–50.View ArticlePubMedGoogle Scholar
- Neil SJ, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature. 2008;451:425–30.View ArticlePubMedGoogle Scholar
- Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature. 2004;427:848–53.View ArticlePubMedGoogle Scholar
- Chiang K, Rice AP. Mini ways to stop a virus: microRNAs and HIV-1 replication. Future Virol. 2011;6:209–21.View ArticlePubMed CentralPubMedGoogle Scholar
- Lahouassa H, Daddacha W, Hofmann H, et al. SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. Nat Immunol. 2012;13:223–8.View ArticlePubMed CentralPubMedGoogle Scholar
- Baldauf HM, Pan X, Erikson E, et al. SAMHD1 restricts HIV-1 infection in resting CD4(+) T cells. Nat Med. 2012;18:1682–7.View ArticlePubMedGoogle Scholar
- Laguette N, Sobhian B, Casartelli N, et al. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature. 2011;474:654–7.View ArticlePubMed CentralPubMedGoogle Scholar
- Silva S, Hoy H, Hake TS, Wong HK, Porcu P, Wu L. Promoter methylation regulates SAMHD1 gene expression in human CD4+ T cells. J Biol Chem. 2013;288:9284–92.View ArticlePubMed CentralPubMedGoogle Scholar
- Houzet L, Yeung ML, De Lame V, Desai D, Smith SM, Jeang KT. MicroRNA profile changes in human immunodeficiency virus type 1 (HIV-1) seropositive individuals. Retrovirology. 2008;5:118.View ArticlePubMed CentralPubMedGoogle Scholar
- Huang J, Wang F, Argyris E, et al. Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. Nat Med. 2007;13:1241–7.View ArticlePubMedGoogle Scholar
- Witwer KW, Watson AK, Blankson JN, Clements JE. Relationships of PBMC microRNA expression, plasma viral load, and CD4+ T-cell count in HIV-1-infected elite suppressors and viremic patients. Retrovirology. 2012;9:5.View ArticlePubMed CentralPubMedGoogle Scholar
- Narasipura SD, Kim S, Al-Harthi L. Epigenetic regulation of HIV-1 latency in astrocytes. J Virol. 2013;88:3031–8.View ArticlePubMedGoogle Scholar
- Schmidtmayerova H, Alfano M, Nuovo G, Bukrinsky M. Human immunodeficiency virus type 1 T-lymphotropic strains enter macrophages via a CD4- and CXCR4-mediated pathway: replication is restricted at a postentry level. J Virol. 1998;72:4633–42.PubMed CentralPubMedGoogle Scholar
- Descours B, Cribier A, Chable-Bessia C, et al. SAMHD1 restricts HIV-1 reverse transcription in quiescent CD4(+) T-cells. Retrovirology. 2012;9:87.View ArticlePubMed CentralPubMedGoogle Scholar
- Goldstone DC, Ennis-Adeniran V, Hedden JJ, et al. HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase. Nature. 2011;480:379–82.View ArticlePubMedGoogle Scholar
- Archin NM, Liberty AL, Kashuba AD, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature. 2012;487:482–5.View ArticlePubMed CentralPubMedGoogle Scholar
- Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem. 2001;276:36734–41.View ArticlePubMedGoogle Scholar
- Zhang H. Reversal of HIV-1 latency with anti-microRNA inhibitors. Int J Biochem Cell Biol. 2009;41:451–4.View ArticlePubMed CentralPubMedGoogle Scholar
- Gray L, Papaionnou C, Cheng W-J, Jacobson J, Lewin S, Churchill M. HIV-1 establishes transcriptional latency in astrocytes in vitro and is responsive to HDACi. Towards an HIV Sure Symposium. 2014:36Google Scholar
- Chandrasekar V, Dreyer JL. microRNAs miR-124, let-7d and miR-181a regulate cocaine-induced plasticity. Mol Cell Neurosci. 2009;42:350–62.View ArticlePubMedGoogle Scholar
- Miska EA, Alvarez-Saavedra E, Townsend M, et al. Microarray analysis of microRNA expression in the developing mammalian brain. Genome Biol. 2004;5:R68.View ArticlePubMed CentralPubMedGoogle Scholar
- Moon JM, Xu L, Giffard RG. Inhibition of microRNA-181 reduces forebrain ischemia-induced neuronal loss. J Cereb Blood Flow Metab. 2013;33:1976–82.View ArticlePubMed CentralPubMedGoogle Scholar
- Saba R, Storchel PH, Aksoy-Aksel A, et al. Dopamine-regulated microRNA MiR-181a controls GluA2 surface expression in hippocampal neurons. Mol Cell Biol. 2012;32:619–32.View ArticlePubMed CentralPubMedGoogle Scholar
- Gray LR, Turville SG, Hitchen TL, et al. HIV-1 entry and trans-infection of astrocytes involves CD81 vesicles. PLoS One. 2014;9, e90620.View ArticlePubMed CentralPubMedGoogle Scholar
- Brack-Werner R, Kleinschmidt A, Ludvigsen A, et al. Infection of human brain cells by HIV-1: restricted virus production in chronically infected human glial cell lines. AIDS. 1992;6:273–85.View ArticlePubMedGoogle Scholar
- Kleinschmidt A, Neumann M, Moller C, Erfle V, Brack-Werner R. Restricted expression of HIV1 in human astrocytes: molecular basis for viral persistence in the CNS. Res Virol. 1994;145:147–53.View ArticlePubMedGoogle Scholar
- Kumar A, Abbas W, Herbein G. HIV-1 latency in monocytes/macrophages. Viruses. 2014;6:1837–60.View ArticlePubMed CentralPubMedGoogle Scholar
- Saksena NK, Wang B, Zhou L, Soedjono M, Ho YS, Conceicao V. HIV reservoirs in vivo and new strategies for possible eradication of HIV from the reservoir sites. HIV AIDS (Auckl). 2010;2:103–22.Google Scholar
- Sahu GK, Cloyd MW. Latent HIV in primary T lymphocytes is unresponsive to histone deacetylase inhibitors. Virol J. 2011;8:400.View ArticlePubMed CentralPubMedGoogle Scholar
- Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.View ArticlePubMedGoogle Scholar
- Dave RS, Khalili K. Morphine treatment of human monocyte-derived macrophages induces differential miRNA and protein expression: impact on inflammation and oxidative stress in the central nervous system. J Cell Biochem. 2010;110:834–45.View ArticlePubMed CentralPubMedGoogle Scholar
- Gottwein E, Mukherjee N, Sachse C, et al. A viral microRNA functions as an orthologue of cellular miR-155. Nature. 2007;450:1096–9.View ArticlePubMed CentralPubMedGoogle Scholar
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.